12/18
08:14 am
prax
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome [Yahoo! Finance]
12/18
08:00 am
prax
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Medium
Report
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
12/12
08:26 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
12/5
08:42 am
prax
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners [Yahoo! Finance]
Medium
Report
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners [Yahoo! Finance]
12/3
08:00 am
prax
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Medium
Report
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
11/26
08:06 am
prax
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting [Yahoo! Finance]
11/26
08:00 am
prax
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Medium
Report
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
11/7
08:36 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $151.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $151.00 price target on the stock.
11/7
08:36 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
11/7
02:19 am
prax
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... [Yahoo! Finance]
11/6
05:00 pm
prax
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Medium
Report
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
11/6
07:30 am
prax
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Low
Report
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
11/1
08:00 am
prax
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Low
Report
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
10/31
02:35 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $143.00 to $163.00. They now have an "outperform" rating on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $143.00 to $163.00. They now have an "outperform" rating on the stock.
10/21
10:17 am
prax
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate [Yahoo! Finance]
10/4
10:24 am
prax
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? [Yahoo! Finance]
9/26
08:00 am
prax
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
Low
Report
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress